Dawen Kou

Title: Innovations by Inventor Dawen Kou

Introduction

Dawen Kou, an accomplished inventor based in Millbrae, California, has made significant contributions to the field of pharmaceutical sciences. He holds two patents that showcase his innovative work in the development of pharmaceutical compositions targeting Bruton's tyrosine kinase, a crucial component in various therapeutic strategies.

Latest Patents

Dawen Kou's recent patents include inventive formulations aimed at improving the efficacy of Bruton's tyrosine kinase inhibitors. The first patent involves dosage form compositions comprising crystalline mesylate salts, chloride salts, and sulfate salts of a specific compound, which is identified as (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one. The invention emphasizes the use of single polymorphs to enhance stability and bioavailability.

His second patent also focuses on dosage form compositions, including pharmaceutical tablet formulations that utilize fumaric acid along with the Bruton's kinase inhibitor free base compound. This patent further explores amorphous solid dispersions combined with polymers to optimize delivery efficacy, in addition to detailing various crystalline salt forms of the inhibitor.

Career Highlights

Dawen Kou is currently associated with Genentech, Inc., a leader in biotechnology and pharmaceuticals. His role in the company has allowed him to work on cutting-edge research and product development, particularly within the realm of targeted therapies for cancer and other diseases.

Collaborations

Throughout his career, Dawen has collaborated with esteemed colleagues such as Chen Mao and Po-Chang Chiang. These collaborations have contributed to his innovative approaches and advancements in the field, further establishing his reputation as a prominent inventor.

Conclusion

Dawen Kou's innovative contributions, particularly in patented formulations targeting Bruton's tyrosine kinase, highlight his commitment to advancing pharmaceutical research. His work at Genentech, Inc., along with his collaborative efforts, continue to pave the way for novel therapeutic options in healthcare.